NEW YORK, March 3, 2017 /PRNewswire/ -- The U.S. Food & Drug Administration's (FDA) Office of Women's Health has agreed to fund a study investigating the possible link between cosmetic talc use and ovarian cancer. A posting on the FDA's website notes that while women are commonly known to use products containing talc for hygiene and cosmetic purposes, talc's effects on the tissues that make up the female genital system have not been adequately investigated.
"Johnson & Johnson is currently facing thousands of talcum powder lawsuits filed on behalf of women who allegedly developed ovarian cancer due to the regular and repeated use of Baby Powder and Shower–to-Shower for feminine hygiene purposes. We are pleased that the FDA is taking steps to investigate this important public health issue," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices, drugs and consumer products. The Firm is offering free legal reviews to victims of ovarian cancer allegedly related to the use of Johnson & Johnson's talc-based powders.
Talcum Powder Lawsuits
According to a recent filing with the U.S. Securities and Exchange Commission, Johnson & Johnson has been named a defendant in at least 3,100 product liability lawsuits involving talcum powder and ovarian cancer. Plaintiffs claim that the company has failed to warn consumers that the long-term application of talcum powder to the female genitals might raise a woman's risk of ovarian cancer, even though studies published as early as the 1970s have suggested that such a link exists. They further assert that Johnson & Johnson's alleged negligence was motivated by a desire to protect profits derived from its talcum powder franchises.
Once of the nation's largest talcum powder litigations has been established in Missouri Circuit Court in St. Louis, which convened three trials last year. All concluded with verdicts in favor of plaintiffs and damage awards totaling $72 million, $70 million and $55 million. The proceedings fourth talcum powder trial is currently underway. (Case No 1422-CC09012-01)
Women who were diagnosed with ovarian cancer following the long-term, regular use of talc-based products for feminine hygiene purposes may be eligible to file their own talcum powder lawsuit. To learn more, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/talcum-powder-lawsuit-news-fda-funds-research-to-investigate-ovarian-cancer-risk-from-cosmetic-talc-bernstein-liebhard-llp-reports-300417764.html
SOURCE Bernstein Liebhard LLP